The formulations covered by the patent are applications of the company’s proprietary RapidMist drug delivery technology and are designed to deliver pain relief medications such as morphine and fentanyl in a convenient alternative to injections and tablets.
Generex’ proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the company’s proprietary RapidMist device.
The RapidMist drug delivery platform, initially applied to insulin with the company’s flagship product, Oral-lyn, can also be applied to small molecule drugs such as morphine and fentanyl, thereby significantly increasing the number of indications for the platform.
“Our mission is to improve drug delivery by making it simpler, more comfortable and more effective, thereby refining and augmenting therapeutic applications and facilitating increased patient compliance,” said Anna Gluskin, president and CEO of Generex.